CD274 and non-small cell lung carcinoma: Immune checkpoint inhibitors against PD-1/PD-L1 are being increasingly adopted as prime treatment measures against metastatic NSCLC, either following chemotherapeutic treatment or in an adjuvant context (Reck et al2016, Gandhi et al2018).